Sun Pharma is voluntarily recalling 3,263 bottles of Levetiracetam, extended release tablets, an anti-epileptic drug, in the US market.
As per the information available on the USFDA website, Sun Pharma Global Fze, a US-based unit of the company, is recalling the drug for failing "dissolution specifications".
The 750 mg tablets in 60-count bottles, were manufactured by Sun Pharmaceutical Industries at Halol, it added.
The recall was initiated by the company on January 21 this year.
It has been classified as a 'Class-II recall' which FDA defined as "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote".
When contacted, a Sun Pharma spokesperson declined to comment.
Shares of Sun Pharma closed at Rs 908.70 apiece, down 0.66 per cent, on the BSE.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
